Design Therapeutics Inc.
DSGN | NASDAQ
$12.55
+$0.31 (+2.53%)
At close: Sep 21, 2026, 4:00 PM ET
$12.56
+$0.01 (+0.08%)
Pre-market:
Sep 22, 2026, 8:51 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 622K | 596K | 537K | 466K | n/a | 5K |
Gross Profit | -622K | -596K | -537K | -466K | n/a | -5K |
Operating Income | -79.47M | -62.38M | -78.19M | -67.59M | -35.83M | -8.56M |
Interest Income | 9.68M | 12.8M | n/a | n/a | n/a | n/a |
Pretax Income | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M |
Net Income | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M |
Selling & General & Admin | 20.34M | 18.03M | 21.13M | 18.98M | 11.05M | 2.5M |
Research & Development | 59.13M | 44.35M | 57.06M | 48.61M | 24.78M | 6.06M |
Other Expenses | -622K | -596K | -537K | -466K | n/a | n/a |
Operating Expenses | 78.85M | 61.79M | 77.65M | 67.13M | 35.83M | 8.55M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 79.47M | 62.38M | 78.19M | 67.59M | 35.83M | 8.56M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 27.19M |
Shares Outstanding (Diluted) | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 27.19M |
EPS (Basic) | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | -0.30 |
EPS (Diluted) | -1.22 | -0.88 | -1.19 | -1.14 | -0.77 | -0.30 |
EBITDA | -69.17M | -48.99M | -66.33M | -62.84M | -35.4M | -8.28M |
EBIT | -69.79M | -49.59M | -66.86M | -63.31M | -35.53M | -8.28M |
Depreciation & Amortization | 622K | 596K | 537K | 466K | 129K | 5K |
Add to Watchlist
Select watchlists to add or remove DSGN